ATE423761T1 - Disubstituierte chalcogenoxime mit antagonistischer wirkung am rar(gamma)- retinoidrezeptor - Google Patents

Disubstituierte chalcogenoxime mit antagonistischer wirkung am rar(gamma)- retinoidrezeptor

Info

Publication number
ATE423761T1
ATE423761T1 AT04815018T AT04815018T ATE423761T1 AT E423761 T1 ATE423761 T1 AT E423761T1 AT 04815018 T AT04815018 T AT 04815018T AT 04815018 T AT04815018 T AT 04815018T AT E423761 T1 ATE423761 T1 AT E423761T1
Authority
AT
Austria
Prior art keywords
rar
gamma
chalcogen
oximes
disubstituted
Prior art date
Application number
AT04815018T
Other languages
German (de)
English (en)
Inventor
Kwok Tsang
Santosh Sinha
Xiaoxia Liu
Smita Bhat
Roshantha Chandraratna
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE423761T1 publication Critical patent/ATE423761T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06Benzothiopyrans; Hydrogenated benzothiopyrans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
AT04815018T 2003-12-26 2004-12-21 Disubstituierte chalcogenoxime mit antagonistischer wirkung am rar(gamma)- retinoidrezeptor ATE423761T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53283503P 2003-12-26 2003-12-26

Publications (1)

Publication Number Publication Date
ATE423761T1 true ATE423761T1 (de) 2009-03-15

Family

ID=34748824

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04815018T ATE423761T1 (de) 2003-12-26 2004-12-21 Disubstituierte chalcogenoxime mit antagonistischer wirkung am rar(gamma)- retinoidrezeptor

Country Status (8)

Country Link
US (2) US7253319B2 (https=)
EP (1) EP1701934B1 (https=)
JP (1) JP2007518719A (https=)
AT (1) ATE423761T1 (https=)
CA (1) CA2551294A1 (https=)
DE (1) DE602004019685D1 (https=)
MX (1) MXPA06007255A (https=)
WO (1) WO2005066115A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
CA2751820A1 (en) * 2009-02-10 2010-08-19 Nippon Soda Co., Ltd. Nitrogen-containing compounds and harmful organism control agents
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
MX2012006776A (es) 2009-12-14 2012-10-05 Merck Patent Gmbh Inhibidores de la esfingosina quinasa.
CA2784647A1 (en) 2009-12-17 2011-07-14 Merck Patent Gmbh Inhibitors of sphingosine kinase
US20140194517A1 (en) * 2013-01-08 2014-07-10 Io Therapeutics, Inc. Treatment of Graft-Versus-Host Disease Disorders using RAR Antagonists
CN110090237B (zh) * 2019-05-30 2021-05-28 四川农业大学 一种用于治疗维生素a中毒所致肝损伤和骨损伤的药物及用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0024982B1 (fr) 1979-08-22 1984-11-28 Léo Jouk Vélo à cadre télescopique adaptable en vélo d'appartement
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
JP4001618B2 (ja) 1991-12-18 2007-10-31 ザ ソールク インスチチュート フォア バイオロジカル スタディズ レチノイド受容体によって仲介される過程の修飾方法およびそれに有用な化合物
EP0638071B1 (en) 1992-12-28 1997-04-09 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5599967A (en) * 1994-12-29 1997-02-04 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5952345A (en) * 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5723666A (en) * 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
PT101919B (pt) * 1996-09-30 2000-01-31 Hovione Sociedade Quimica Sa Um processo para a purificacao de tohexol
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5760276A (en) * 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US6037488A (en) * 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6313168B1 (en) * 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20030114482A1 (en) * 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
SI1324970T1 (sl) * 2000-10-02 2009-02-28 Hoffmann La Roche Retinoidi za zdravljenje emfizema
US20020193403A1 (en) * 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia

Also Published As

Publication number Publication date
WO2005066115A2 (en) 2005-07-21
EP1701934B1 (en) 2009-02-25
CA2551294A1 (en) 2005-07-21
WO2005066115A8 (en) 2005-10-27
DE602004019685D1 (de) 2009-04-09
MXPA06007255A (es) 2006-08-18
US7253319B2 (en) 2007-08-07
EP1701934A2 (en) 2006-09-20
JP2007518719A (ja) 2007-07-12
US7432388B2 (en) 2008-10-07
WO2005066115A3 (en) 2006-01-12
US20080097119A1 (en) 2008-04-24
US20050165095A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
CY2009004I1 (el) Υποκατεστημενες με φθοριο κυκλοαλκανοϊνδολες και η χρηση τους ως ανταγωνιστες των υποδοχεων προσταγλανδινης d2
DE60314347D1 (de) Betriebsmittelverwaltungsgerät
DE602004025349D1 (de) Halbleiterbauelement mit bandlücken-angepasstem üb
CY1108378T1 (el) 4-υποκατεστημενα παραγωγα 1-αμινοκυκλοεξανιου για την χρησιμοποιηση σαν προσδεματα υποδοχεα orl1 ή οπιακου υποδοχεα mu
EP1471972A4 (en) MICROELECTRONIC STIMULATOR ARRAY
ATE404537T1 (de) Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
NI201100118A (es) N-oxipiperidinas espiroheterociclicas como pesticidas.
FI20030662L (fi) Laitteenhallinta
ITRM20030188A0 (it) Attrezzatura per il collaudo automatico di dispositivi a semiconduttori.
AU2003253441A1 (en) Spiro compound and organic luminescence device using the same
EP1794256A4 (en) NEW CONNECTION AND THIS USING ORGANIC LIGHT-EMITTING DEVICE (2)
MXPA05001354A (es) Piperidina-ftalazonas sustituidas por pirrolidinodiona como inhibidores pde4.
ECSP045255A (es) Cumarinas utiles como biomarcadores
DK1499316T3 (da) (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister
ITTO20020723A0 (it) Struttura di manto erboso sintetico
CY1107156T1 (el) Νεα μεθοδος συνθεσης του (7-μεθοξυ-3,4-διυδρο-1-ναφθαλινυλ) ακετονιτριλιου και εφαρμογη στη συνθεση της αγομελατινης
ATE423761T1 (de) Disubstituierte chalcogenoxime mit antagonistischer wirkung am rar(gamma)- retinoidrezeptor
ITTO20031020A1 (it) Apparecchiatura di volatilizzazione.
EP1471387A3 (en) Photosensitive composition and compound used thereof
DK1636221T3 (da) 3-Heterocyclyl-azetidin-forbindelser, som er nytte som NK1/NK2 receptorantagonister
DE602004026022D1 (de) Sulfoniumsalze als Photoinitiatoren
NO20044373L (no) Azetidinderivater som CCR-3-reseptorantagonister
EP3530658A3 (en) Heterocyclic compound and organic light-emitting device including the same
DE60328272D1 (de) Diazabicycloalkan-derivate mit nk1-antagonistischer wirkung
DE602004005801D1 (de) Bandbreitenmanagement gestützt auf statistische Messungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties